• Vaccine Name: Brucella melitensis rBtuB Hia FlgK subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009524
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Goat
• Antigen: rBtuB, Hia, FlgK peptides
• Adjuvant: t reported
• Preparation: A cocktail of three peptides (rBtuB, Hia, FlgK) from Brucella melitensis was used; adjuvant was included but not specified. (De et al, 2023)
• Description: The study evaluated the goat Th1/Th2 immune response to a cocktail of three Brucella melitensis peptides (rBtuB-Hia-FlgK) previously shown to induce antigen-specific immune responses in rodent models. Efficacy: The peptide cocktail induced an increase in CD4+/CD8+ T cells starting at day 15 and persisting to day 80. IFN-γ, TNF-α, and IL-2 mRNA expression were induced by day 15, with IFN-γ levels maintained at day 80. Although IFN-γ production was lower than that induced by Rev-1 at day 15, this may be due to sampling timing. Immune response: The vaccine induced a Th1-type cellular immune response characterized by increased CD4+/CD8+ T cell proliferation and production of Th1 cytokines (IFN-γ, TNF-α, IL-2), similar to the response induced by the live attenuated Rev-1 vaccine. The results suggest the peptide cocktail can induce cellular immunity comparable to an attenuated vaccine. (De et al, 2023)

Goat Response

• Immune Response: The vaccine induced a Th1-type cellular immune response characterized by increased CD4+/CD8+ T cell proliferation and production of Th1 cytokines (IFN-γ, TNF-α, IL-2), similar to the response induced by the live attenuated Rev-1 vaccine. The results suggest the peptide cocktail can induce cellular immunity comparable to an attenuated vaccine. (De et al, 2023)
• Efficacy: The peptide cocktail induced an increase in CD4+/CD8+ T cells starting at day 15 and persisting to day 80. IFN-γ, TNF-α, and IL-2 mRNA expression were induced by day 15, with IFN-γ levels maintained at day 80. Although IFN-γ production was lower than that induced by Rev-1 at day 15, this may be due to sampling timing. (De et al, 2023)
• Description: Twenty-eight goats were divided into four groups and immunized with the peptide cocktail, adjuvant alone, PBS, or the Rev-1 vaccine. Peripheral blood samples were collected on days 0, 15, and 80 post-inoculation. CD4+ and CD8+ T cell proliferation and cytokine production (Th1: IL-2, IL-12, TNF-α, IFN-γ; Th2: IL-4, IL-5, IL-10) were evaluated. (De et al, 2023)